Profarma - 3Q16 earnings release

1. NOVEMBER 9, 2016

2. 2
• The only Brazil’s mixed market player that features exposure and expansion
capacity in the segments of Retail, Hospital & Specialties and Distribution;
• Strategic partnership with AmerisourceBergen, the world’s largest player in the
pharmaceutical specialties, resulting in the creation of the company Profarma
Specialty since 2014;
• The Company carried out five acquisitions between 2012-2016, including its
entry into the Retail pharmaceutical segment, and the attainment of a market
position as 6th largest player within this segment in the country;
• Proven capacity to integrate acquisitions, combining all group companies in the
SAP plataform, BI Cognos and Hyperion.

3. 3

4. Specialties(*)
3Q15 3Q16
Retail(**)
3Q15 3Q16
Consolidated (*)(**)
3Q15 3Q16
Pharmaceutical
Distribution
3Q15 3Q16
4
Gross Revenues
Gross Profit
SGA
Ebitda
(**) pro forma figures: 100% of revenues from Tamoio in 3Q15.
(*) pro forma figures: 100% of revenues from Specialties (3Q15 and 3Q16).
201.4
22.3
16.4
5.6
241.5
23.5
20.0
1.9
191.0
55.8
51.5
2.5
198.1
60.0
51.2
7.1
1,311.2
162.0
132.4
29.1
1,367.3
177.7
140.0
38.9
1,010.4
83.9
64.5
21.2
1,040.6
94.2
68.7
30.0

6. Specialties
6
Gross Revenues Evolution
(R$ million)
Pharmaceutical Distribution
Sales increased by 3.0% year-over-
year
Sales increased by 19.9% in
comparison with 3Q15
Sales increased by 3.7% year-over-
year
Accounting Consolidated Gross Revenues
pro forma Consolidated Gross Revenues: 3Q15 – 100% of Tamoio
and Specialties / 2Q16 and 3Q16 – 100% of Specialties
Retail
3Q15 2Q16 3Q16
1,072.2
238.9
1,311.2
1,149.6
207.6
1,357.3
1,162.8
204,5
1,367.3
0.7%
4.3%

7. Pharmaceutical Distribution Specialties(**) Retail
7
Gross Revenues Evolution
(R$ million)
Accounting Gross Revenues
pro forma additional Gross
Revenues
(*) pro forma figures: 100% of Tamoio and Drogasmil / Farmalife
(**) pro forma figures: 100% of Specialties
3Q15 2Q16 3Q16 3Q15 2Q16 3Q16 3Q15(*) 2Q16 3Q16
1,010.4 1,003.2
3.7%
3.0%
201.4
246.5 241.5
-2.0%
19.9%
78.6
3.7%
112.4
191.0
198.1
-3.2%
1,040.6 204.8

8. 8
Gross Profit
(R$ million and % Net Revenues)
3Q163Q15 2Q16 3Q163Q15 2Q16
(*) pro forma data: 3Q15 – 100% of Tamoio and Specialties / 2Q16 and 3Q16 – 100% of Specialties
pro forma(*)
11.6%
108.2
17.8%
177.6
15.2%
154.1
17.6%
14.0%
162.0
208.4
14.9%
177.7

9. 9
Operating Expenses – SGA
(R$ $ million and % Net Revenues)
3Q163Q15 2Q16 3Q163Q15 2Q16
(*) pro forma data: 3Q15 – 100% of Tamoio and Specialties / 2Q16 and 3Q16 – 100% of Specialties
11.5%
132.4
11.8%
139.9
11.7%
140.0
9.6%
12.0% 11.8%
90.2
119.6 120.0
pro forma(*)

10. 10
Adjusted EBITDA and Adjusted EBITDA Margin
(R$ million and % Net Revenues)
3Q163Q15 2Q16 3Q163Q15 2Q16
(*) pro forma data: 3Q15 – 100% of Tamoio and Specialties / 2Q16 and 3Q16 – 100% of Specialties
2.2%
21.0
5.4%
54.1
3.5%
35.4
2.5%
29.1
5.1%
60.2
3.3%
38.9
pro forma(*)
-34.7%
68.6%
-35.3%
33.8%

11. 11
Net Profit
(R$ million and % Net Revenues)
Net Profit
Adjusted Net Profit
pro forma Net Profit
pro forma Adjusted Net Profit
(*) pro forma data: 3Q15 – 100% of Tamoio and Specialties / 2Q16 and 3Q16 – 100% of Specialties
8.5
3Q15
(4.4)
-0.4% 0.6%
-1.0%
2Q16
7.5
(12.2)
(6.4)
3Q16
-0.7%
0.8%
-0.9%
(9.5)
2Q16
(4.9)
1.0
16.0
-0.5%
1.6%
0.1%
(2.9)
15.0
(0.1)
-0.3%
1.3%
0.0%
3Q15 3Q16
pro forma(*)

12. Cash Flow
(R$ million)
* Average
(1) Average of Gross Revenues in the Quarter
(2) Average of COGS in the Quarter
(3) Average of COGS in the Quarter
(4) The account was based on the average gross sale and CGS, excluding Specialties
division and Tamio’s chain
(5) The account was based on the average gross sale and CGS, excluding Specialties
division
Cash Cycle
(Days)
Cash Flow Generated /
Used) in Operating Activities
Internal Cash Generation
Operating Assets Variation
Cash Flow (Used)
in Investing Activities
Cash Flow Generated /
(Used) by Financing Activities
Net Increase /
(Decrease) in Cash
12
Consolidated
Pro forma
Cash Cycle *
Accounts Receivable¹
Inventories²
Accounts Payable³
Consolidated Pharma PFS. Retail
3Q16 3Q15 3Q1652Q1653Q154
3Q163Q163Q16
69.6
19.8
49.8
(10.2)
(30.9)
28.4
58.2
18.5
39.7
(5.8)
(45.0)
7.4
40.2
63.1
52.1
51.235.4
44.5
54.1
63.2
44.3
71.2
60.5
55.2
15.3
63.8
39.4
39.746.3
56.7
42.3
52.7
46.7
46.3
56.4
55.9

13. 13
Capex
(R$ million)
Indebtedness: Net Debt and Net Debt /
EBITDA (R$ million)
Capex
3Q16
OtherIT
Machinery and
Equipment
3Q15 2Q16 3Q16
10.92.0
1.4
7.4
301.1
428.4
397.8
4.0x 3.8x
3.1x

15. Financial Data
(R$ million and % Net Revenues)
3Q15 3Q163Q15 3Q163Q15 3Q163Q15 3Q16
15
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
3.3
2.4
7.7
7.4
10.5
9.6
1,040.6
1,010.4

17. 17
Financial Data (*)
(R$ million and % Net Revenues)
3Q15 3Q163Q15 3Q163Q15 3Q163Q15 3Q16
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
(*) Basis 100%
0.9
3.0
9.08.9
10.6
12.0
241.5
201.4

19. 19(*) 3Q15 pro forma figures: 100% of Tamoio
Financial Data
(R$ million and % Net Revenues)
3Q15* 3Q163Q15* 3Q163Q15* 3Q163Q15* 3Q16
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
3.6
1.3
25.8
26.9
30.3
29.2
198.1
191.0

20. 20
Total Sales Growth
(%)
SSS Mature Stores
(%)
Same Store Sales
(%)
Monthly Average
Store's Sales (mature)
(R$ thousand)
(*) 3Q15 pro forma figures: 100% of Tamoio
3Q15 3Q162Q16 3Q15 3Q162Q163Q15 3Q162Q16 3Q15 3Q162Q16
3.7%
10.5% 10.8 %
-6.8 p.p.
-7.0 p.p.
5.3%
2.5%
8.5%
-2.8 p.p.
-6.0 p.p.
6.0%
3.9%
11.1%
-2.1 p.p.
-7.2 p.p.
564.0
589.7
550.2
2.5%
-4.4%

21. 21
2 Opening
1 Close-downs
2 Reformulated
103 Mature
Average Ticket
(R$)
# of Stores
(units)
(*) 3Q15 pro forma figures: 100% of Tamoio
3Q15 3Q162Q163Q15 2Q16 3Q16
34,07
35,8335,82
5.2%
0.0%
128
129
130
1.6%
0.8%

23. 23
Company Analyst Telephone E-mail
Brasil Plural Guilherme Assis +55 (11) 3206 8285 guilherme.assis@brasilplural.com.br
BTG Pactual Rodrigo Gastim +55 (11) 3383-2468 rodrigo.gastim@btgpactual.com
BofA Merrill Lynch Roberto Otero +55 (11) 2188-4119 roberto.otero@baml.com
Eleven Financial Raul Grego Lemos +55 (11) 4302-3340 rg@elevenfinancial.com
J.P. Morgan Joseph Giordano +55 (11) 4950-3020 joseph.giordano@jpmorgan.com
Votorantim Paulo Prado +55 (11) 5171 5625 paulo.prado@votorantimcorretora.com.br

24. Max Fischer - CFO e IRO & Beatriz Diez - IRM
www.profarma.com.br/ir | Phone.: 55 (21) 4009-0276 | E-mail: ri@profarma.com.br